A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Acalabrutinib, a Selective and Irreversible Bruton's Tyrosine Kinase Inhibitor, in Japanese Adult Patients With Advanced B-cell Malignancies

Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Acalabrutinib, a Selective and Irreversible Bruton's Tyrosine Kinase Inhibitor, in Japanese Adult Patients With Advanced B-cell Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Acalabrutinib (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 1 Feb 2021 to 27 Jan 2021.
    • 18 Jul 2017 Planned primary completion date changed from 1 Feb 2021 to 27 Jan 2021.
    • 18 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top